Indoximod
Phase 2Small molecule
Indoximod is one of 71 small molecule programs targeting Newly Diagnosed. It is currently in Phase 2.
2
Indications
10
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
83 competitors in Newly Diagnosed
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Cytosar
TevaPhase 3
Rituxan
RochePhase 3
Oncovin
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Darzalex
Johnson & JohnsonPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Oncovin
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Brain Tumors2 trials
Metastatic Melanoma2 trials
Non-Small Cell Lung Cancer1 trial
Brain Cancer1 trial
3 more indications
Newly Diagnosed1 trial
Metastatic Prostate Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Indoximod. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNewLink Genetics Corporation